Clinical Study

Stronger Correlation between Interleukin 18 and Soluble Fas in Lupus Nephritis Compared with Mild Lupus

Mohammad Reza Hatef,1 Maryam Sahebari,1 Zahra Rezaieyazdi,1 Mohammad Reza Nakhjavani,2 and Mahmoud Mahmoudi3

1 Rheumatology, Rheumatic Diseases Research Center (RDRC), School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Rheumatology, Rheumatology Department, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
3 Immunology, Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Maryam Sahebari; sahebarim@mums.ac.ir

Received 16 January 2013; Accepted 13 February 2013

Academic Editors: A. M. Huber, A. Spreafico, and A. Wong

Copyright © 2013 Mohammad Reza Hatef et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lupus nephritis (LN) is a major cause of morbidity in patients with systemic lupus erythematosus (SLE). Several cytokines and apoptotic markers such as IL-18 and soluble Fas (sFas) have been assumed to play a role in the pathogenesis of LN. Previous studies confirmed that serum concentrations of sFas and IL-18 are increased in SLE. However, only a few studies have suggested a possible correlation between IL-18 and sFas. This study was planned to continue our previous study on the correlation between those markers to evaluate this correlation in LN. Thirty-two patients with only LN and 46 patients without any major organ involvement participated in this study. SLEDAI score (except for scores related to nephritis) was the same in these two groups. In both groups, patients with any other major organ involvement were excluded. We found a significant rise in the serum concentrations of sFas (\(P = 0.03\)) and IL-18 (\(P = 0.02\)) in patients with proteinuria compared to those without it. This study showed that the correlation between sFas and IL-18 in LN (\(P < 0.001, r_p = 0.5\)) is significantly stronger than it is in mild SLE (\(P < 0.001, r_p = 0.4\)) with similar nonrenal SLEDAI score (\(P = 0.032, z = 1.85\)). Between these two serum markers, sFas is the only predictor of proteinuria.

1. Introduction

Lupus nephritis is a serious complication of SLE. Proteinuria is the most frequently observed abnormality in lupus nephritis [1, 2]. Although the precise etiology of LN is not entirely known, several factors have been proposed in the initiation and progression of LN. Two important factors that are suggested to be involved in that are apoptosis imbalance [3] and overproduction of several cytokines like IL-18 [4].

Researchers have emphasized the pathogenic function of IL-18 and Fas/Fas ligand pathway in autoimmune-related diseases like lupus [5–7]. Besides, recent evidence suggests that IL-18- and Fas-mediated apoptosis may relate to each other by the proapoptotic effects of IL-18. IL-18 is able to enhance Fas/Fas ligand expression in specific cells [8, 9].

Fas (Apo/1-CD95) and its ligand belong to the tumor necrosis factor/nerve growth factor superfamily [10–16]. IL-18, a TNF-α inducer and Fas/Fas ligand expressor, is a crucial factor for the autoimmune process [5, 8, 9, 17–19]. Although the role of IL-18 and sFas has been elucidated separately, in the pathogenesis of LN [1, 4, 20], there is little evidence about the correlation between sFas and IL-18 in autoimmune diseases. Only a few studies mentioned that infections could raise serum sFas and IL-18 concentrations through increasing and/or enhancing apoptotic turnover of defensive cells [21–26]. Very few studies about autoimmune diseases have
addressed this correlation too. Chen et al. [27] demonstrated the influence of IL-18 on the apoptosis of peripheral blood lymphocytes in adult onset Still's disease (AOSD), SLE, and healthy participants. In our previous study, we also demonstrated that sFas and IL-18 rise in correlation with disease activity in lupus [28].

A large and growing body of literature expressed the role of IL-18 and sFas in lupus nephritis apart from each other [4, 18, 20, 29–37], and some investigators referred to the local production of IL-18 in glomeruli resulting in local effects in the pathogenesis of LN [38]. However, far too little attention has been paid to the correlation between these two serum markers in LN.

To continue our previous study, in this paper, we carefully examined the correlation between sFas and IL-18 serum concentrations in lupus nephritis compared with mild lupus. The main question in the current study was whether the correlation between sFas and IL-18 in LN is stronger than that correlation in mild lupus. For this purpose, we designed this study by the selection and comparison of two groups of patients including lupus nephritis patients without any other major organ involvement and mild lupus patients including those without any major organ involvement.

2. Materials and Methods

2.1. Patients and Controls. This is a prospective case-control, cross-sectional study in which seventy-eight SLE patients including 75 (96.2%) women and 3 (3.8%) men participated. Thirty-two (41%) patients had proteinuria more than 500 mg in a 24-hour urine collection (case or severe SLE group), and 46 (59%) patients had no kidney involvement as defined by normal urinary sedimentation, creatinine clearance more than 80%, without previous history of renal involvement (control or mild SLE group). All patients have been diagnosed SLE by fulfilling at least four criteria of the American College of Rheumatology (ACR) revised criteria for SLE [34]. Renal involvement in this study was defined as proteinuria more than 500 mg in a 24-hour urinary collection sample, nephritic hematuria or pyuria, or GFR less than 80%. A provided checklist recorded patients’ demographic data including important laboratory parameters and medications. SLEDAI questionnaire was completed for each participant. Pregnant or postpartum women, patients with past or present history of malignancy, concurrent infection, recent trauma, smoking or addiction, overlap syndromes, chronic renal failure, and other systemic problems not related to SLE like a history of hepatitis or liver disease were excluded from the study. Since reduction in glomerular filtration rate (GFR) increases serum sFas concentrations [35], we also excluded all patients with the GFR less than 80%. Thus, the aim of this study was the evaluation of sFas and IL-18 serum levels in the lupus renal involvement. Patients with other major organ involvements at the sampling time, like heart or central nervous system involvement, vasculitis, and psychosis were also excluded. Sera was obtained from patients and kept frozen at −20°C prior to measurements of IL-18 and sFas as described below. All participants signed an informed consent. This study was approved by the Mashhad University of Medical Sciences ethic committee.

2.2. IL-18 and Soluble Fas (CD95/Apo-1) ELISA. All samples were coded and the laboratory technicians were kept blind about the cases and controls. sFas concentrations were detected using a sAPO-1/FAS BMS245 ELISA kit (Bender Medsystems, Austria) according to the manufacturer’s instructions. The overall intra- and interassay coefficients of variation in this study were 4.5% and 3.1%, respectively. IL-18 concentrations were measured with BMS267 ELISA kit (Bender Medsystems, Austria) according to the manufacturer’s instructions. The overall intra- and interassay coefficients of variation in this study were 6.5% and 8.1%, respectively.

2.3. Statistical Analysis. The statistical analyses were performed with the SPSS 11.5 program (SPSS Inc., Chicago, IL, USA). Values are reported as mean ± SD for normally distributed variables and median with interquartile range (IQR) for others. To assess variables that are not normally distributed, “Kolomogrov-Smirnov” test was used. Patient’s demographics and clinical characteristics were analyzed using “student’s t-test” for continuous variables, “Mann-Whitney test” and “Kruskal-Wallis test” for nonparametric variables, and “chi-square test” for categorical variables. The correlation coefficient was calculated according to Pearson and Spearman’s rank correlation coefficient test based on the data type. Multivariate logistic regression analyses were performed to evaluate the association between IL-18 and sFas serum levels with the existence of proteinuria. “Significance of the difference between two correlation coefficients” was applied to estimate the power of correlation between sFas and IL-18 among case and control groups.

3. Results

3.1. Baseline Analysis. One-sample Kolmogorov-Smirnov test was used to evaluate distribution of age, IL-18, sFas, C3, C4, ESR, anti-dsDNA, and 24-hour urine protein excretion parameters in three groups including all participants, severe lupus, and mild lupus separately. Table 1 presents distribution of these parameters in patients.

3.2. Clinical Characteristics. Seventy-eight lupus patients enrolled in this study. Thirty-two of them had proteinuria. The mean duration of disease was 4 years. The median with interquartile range (IQR) of 24-hour urine protein excretion was 1.2 (0.6–2) gram. The mean level of creatinine in the patients was 0.7 (±0.2) mg/dL. The mean (±SD) or median (IQR) of the age, IL-18, sFas, C3, C4, ESR, and anti-dsDNA in all participants and the statistical difference of these parameters between the 2 groups are shown in Table 1.

Twenty-four patients with proteinuria underwent renal biopsy. Among these, 20 cases had class IV LN, 2 had class V LN, and 2 cases had class II LN.

As Table 1 shows, there were not any significant difference in important laboratory parameters like a rise in anti-dsDNA and ESR or a decrease in C3, C4, thrombocytopenia,
### Table 1: Important demographic and laboratory data of the patients.

| Variables                        | Total patients (n = 78) mean (±SD) or IQR* | Patients without proteinuria (n = 46) mean (±SD) or IQR | Patients with proteinuria (n = 32) mean (±SD) or IQR | P value (patients with and without proteinuria) |
|----------------------------------|---------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------|
| Age (years) range                 | 30.14 (±9.5) 15–62                          | 28.98 (±6.8) 20–43                                      | 29.47 (±8.9) 15–62                                    | 0.6**                                           |
| C3 (mg/dL) range                  | 41 (30.75–97) 5–163                         | 41 (33–100) 5–163                                      | 62.44 (±41.4) 5–150                                    | 0.5**                                           |
| C4 (mg/dL) range                  | 14 (27–10) 4–53                             | 15 (10–32) 4–53                                       | 18.41 (±12.5) 4–49                                    | 0.5**                                           |
| Anti dsDNA range                  | 2 (1–7) 1–30                                | 4.43 (±5.4) 1–30                                      | 1.5 (1–8) 1–15                                        | 0.6***                                          |
| Cr (mg/dL) range                  | 0.77 (±0.26) 1.25–5                           | 0.78 (±0.26) 1.25–5                                    | 0.77 (±0.26) 1.25–5                                    | 0.82**                                          |
| ESR (mm/h) range                  | 25 (18–54) 2–150                            | 25 (17–47) 2–150                                       | 48.81 (±39.4) 2–150                                    | 0.1***                                          |
| IL-18 (pg/mL) range               | 479 (287–775) 20–1245                        | 399.23 (±287.5) 20–1125                                 | 615.57 (±342.6) 20–1125                                 | 0.02**                                          |
| sFas (pg/mL) range                | 210 (148–195) 1–2260                         | 168 (134–292) 1–2260                                   | 409.38 (±416.3) 1–2260                                  | 0.03**                                          |
| Number of Lymphopenic patients (%)| 27 (34.6) 100                                 | 17 (36.9) 100                                           | 10 (31.25) 100                                          | 0.60****                                        |
| Number of thrombocytopenic patients (%) | 9 (11.53) 5 (10.86)                      | 5 (10.86) 4 (12.5)                                      | 4 (12.5) 4 (12.5)                                       | 1****                                           |
| Number of patients with hemolytic anemia (%) | 3 (3.8) 2 (4.34)                          | 2 (4.34) 2 (4.34)                                      | 1 (3.1) 1 (3.1)                                         | 1****                                           |

* Normally distributed are presented by mean (±SD), not normally distributed data are presented by interquartile (IQR) range.
** Student’s t-test.
*** Mann-Whitney test.
**** Chi-square test.

lymphopenia, and hemolytic anemia between the two groups. The mean of SLEDAI score without renal involvement criteria (proteinuria, hematuria, and pyuria) in LN patients was 8.1 ± 5.7 and in the control group it was 10.9 ± 7.2. There was not any statistical difference in nonnephrotic SLEDAI criteria between the two groups (P = 0.6, t = -1.8).

#### 3.3. sFas and IL-18 in the Two Groups of Patients with and without Proteinuria.

Serum levels of sFas (P = 0.03) and IL-18 (P = 0.02) in the patients with proteinuria were significantly higher than patients without proteinuria (Table 1). We found a significant positive correlation between serum levels of sFas and IL-18 in patients with proteinuria (P < 0.001, r_p = 0.5) (Figure 1). There was also a positive correlation between these two parameters in patients without proteinuria (P < 0.001, r_p = 0.4) (Figure 2). After applying significance of the difference between two correlation coefficients, correlation coefficient of sFas and IL-18 in the patients with proteinuria was found greater than those without it (z = 1.85, P = 0.032, one-tailed). As we mentioned above, these two groups did not show any statistical difference in nonnephrotic SLEDAI scores.

![Figure 1: Correlation between serum values of sFas and IL-18 in patients with proteinuria (P < 0.001, r_p = 0.5).](image)

#### 3.4. Medications.

Sixty-six of our patients were treated with prednisolone. The mean IQR dose of prednisolone was 10 (5–30) mg/d. There was no correlation between sFas (P = 0.42, r = 0.1) and IL-18 (P = 0.33, r = 0.12) serum levels.
justified by observations which showed that local production of IL-18 in glomeruli is more important than systemic IL-18 for induction of LN [18, 38]. Faust et al. showed that in MRL-Fas−/− mice with autoimmune lupus nephritis, renal tubular epithelial cell-derived interleukin-18 upregulation correlates with disease activity [30]. Furthermore, these positive correlations were consistent despite immunosuppressive therapy. In other words, it can be supposed that this correlation may be stronger in untreated patients, although this needs to be verified with further studies.

However, our study is a cross-sectional study with a limited number of patients, which does not have enough power to confirm the aforementioned hypothesis. In conclusion, one can assume that a balance among various immunologic pathways such as apoptotic pathways, cytokine production and synthesis of their soluble receptors or inhibitors, predict the natural course of a disease. Based on our findings, we propose that in lupus nephritis, IL-18 and sFas have interrelated effects on proteinuria. Further research to investigate the association of IL-18 and sFas and their exact role in induction or maintaining of lupus nephritis is required.

5. Conclusions

In brief, the current study illustrated that serum values of sFas and IL-18 are significantly higher in lupus patients with proteinuria compared with patients without proteinuria. In addition, the correlation between sFas and IL-18 is significantly stronger in LN patients compared to patients without LN. Moreover, sFas serum values are better predictors than IL-18 for proteinuria. The stronger correlation between sFas and IL-18 in LN compared with mild lupus emphasizes the important pathogenic role of these two markers in kidney damage.

Acknowledgments
This research was financially supported by Mashhad University of Medical Sciences, chancellor of research (Grant no. 85077). The authors would like to thank all patients for their kind participation. Maryam Sahebari currently works at Rheumatic Diseases Research Center (RDRC), Ghaem Hospital, Ahmad Abad Street, P.O. Box 91766-99199, Mashhad, Iran.

References
[1] R. Saxena, T. Mahajan, and C. Mohan, “Lupus nephritis: current update,” Arthritis Research & Therapy, no. 13, article 240, 2011.
[2] F. A. Houssiau, C. Vasconcelos, D. D’Cruz et al., “Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide,” Arthritis & Rheumatism, vol. 46, no. 8, pp. 2121–2131, 2002.
[3] M. Alecu, G. Coman, and S. Alecu, “Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus,” Romanian Journal of Internal Medicine, vol. 38, pp. 83–88, 2000.
[4] A. Gigante, M. L. Gasperini, A. Afeltra et al., “Cytokines expression in SLE nephritis,” European Review for Medical and Pharmacological Sciences, vol. 15, no. 1, pp. 15–24, 2011.
[5] J. M. Kahlenberg, S. G. Thacker, C. C. Berthier, C. D. Cohen, M. Kretzler, and M. J. Kaplan, “Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus,” The Journal of Immunology, vol. 187, no. 11, pp. 6143–6156, 2011.

[6] K. Nozawa, N. Kayagaki, Y. Tokano, H. Yagita, K. Okumura, and H. Hasimoto, "Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases," Arthritis & Rheumatism, vol. 40, no. 6, pp. 1126–1129, 1997.

[7] L. E. Munoz, C. Van Bavel, S. Franz, J. Berden, M. Herrmann, and J. van der Vlag, “Apoptosis in the pathogenesis of systemic lupus erythematosus,” Lupus, vol. 17, no. 5, pp. 371–375, 2008.

[8] H. Kitaura, M. Tatamiya, N. Nagata et al., “IL-18 induces apoptosis of adherent bone marrow cells in TNF-α-mediated osteoclast formation in synergy with IL-12,” Immunology Letters, vol. 107, no. 1, pp. 22–31, 2006.

[9] T. Ohtsuki, M. J. Micallef, K. Kohno, T. Tanimoto, M. Ikeda, and M. Kurimoto, “Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells,” Anticancer Research, vol. 17, no. 5A, pp. 3253–3258, 1997.

[10] M. Bijl, G. Horst, P. C. Limburg, and C. G. M. Kallenberg, “Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity,” Lupus, vol. 10, no. 12, pp. 866–872, 2001.

[11] M. Sahin, O. Aydintug, S. E. Tunc, H. Tutkak, and M. Naziroglu, “Serum soluble Fas levels in patients with autoimmune rheumatic diseases,” Clinical Biochemistry, vol. 40, no. 1-2, pp. 6–10, 2007.

[12] M. Sahebari, M. R. Hatef, Z. Rezaieyazdi, M. Abbasi, B. Abbasi, and M. Mahmoudi, “Correlation between serum levels of soluble fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran,” Archives of Iranian Medicine, vol. 13, no. 2, pp. 135–142, 2010.

[13] J. Cheng, T. Zhou, C. Liu et al., “Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule,” Science, vol. 263, no. 5154, pp. 1759–1762, 1994.

[14] F. Silvestris, D. Grinello, M. Tucci, P. Cafforio, and F. Dammacco, “Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus,” Lupus, vol. 12, no. 1, pp. 8–14, 2003.

[15] E. Telegina, T. Reshetnyak, A. Moshinikova et al., “A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus,” Immunology Letters, vol. 122, no. 1, pp. 12–17, 2009.

[16] F. Silvestris, P. Cafforio, M. Tucci, A. del Prete, and F. Dammacco, "VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-1), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease," Molecular Medicine, vol. 6, no. 6, pp. 509–526, 2000.

[17] H. P. Carroll, V. Paunovic, and M. Gadina, “Signalling, inflammation and arthritis: crossed signals: the role of interleukin-15 and -18 in autoimmuneitiy,” Rheumatology, vol. 47, no. 9, pp. 1269–1277, 2008.

[18] P. Reddy, "Interleukin-18: recent advances," Current Opinion in Hematology, vol. 11, no. 6, pp. 405–410, 2004.

[19] T. Dao, K. Ohashi, T. Kayano, M. Kurimoto, and H. Okamura, "Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells," Cellular Immunology, vol. 173, no. 2, pp. 230–235, 1996.

[20] C. Shimizu, T. Fujita, Y. Fuke et al., "High circulating levels of interleukin-18 binding protein indicate the severity of glomerular involvement in systemic lupus erythematosus," Modern Rheumatology, vol. 22, no. 1, pp. 73–79, 2012.

[21] E. Marin-Serrano, C. Rodriguez-Ramos, F. Diaz, L. Martin-Herrera, and J. Girón-González, "Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin," Journal of Viral Hepatitis, vol. 13, no. 4, pp. 230–234, 2006.

[22] H. Nakae, Y. J. Zheng, H. Wada, K. Tajimi, and S. Endo, "Involvement of IL-18 and soluble Fas in patients with postoperative hepatic failure," European Surgical Research, vol. 35, no. 2, pp. 61–66, 2003.

[23] S. El-Masry, M. Lotfy, W. A. Nasif, I. M. El-Kady, and M. Al-Badrawy, "Elevated serum level of interleukin (IL)-18, interferon (IFN)-c and soluble fas in patients with pulmonary complications in tuberculosis," Acta Microbiologica et Immunologica Hungarica, vol. 54, no. 1, pp. 65–77, 2007.

[24] S. Imai, N. Sato, Y. Inoue, and S. Endo, "A study of interleukin 18 and sFas in septic multiple organ dysfunction syndrome," Journal of the Iwate Medical Association, vol. 57, no. 5, pp. 497–503, 2005.

[25] M. Kazu, Y. Ami, T. Nakasone et al., "Higher levels of IL-18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV," Virology, vol. 313, no. 1, pp. 8–12, 2003.

[26] A. Sharma, A. Chakrabarti, A. Das, R. K. Dhiman, and Y. Chawla, "Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis," Immunology, vol. 128, no. 1, part 2, pp. e514–e522, 2009.

[27] D. Y. Chen, T. Y. Hsieh, C. W. Hsieh, F. J. Lin, and J. L. Lan, "Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease," Arthritis Care and Research, vol. 57, no. 8, pp. 1530–1538, 2007.

[28] M. Sahebari, Z. Rezaieyazdi, M. J. Nakhjavani, M. Hatef, M. Mahmoudi, and S. Akhlaghi, "Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus," Rheumatology International, vol. 32, no. 3, pp. 601–606, 2012.

[29] P. Y. Tsai, S. M. Ka, J. M. Chang et al., "Antroquinonol differentially modulates T cells activity, reduces IL-18 production, but enhances Nr2f2 activation in accelerated severe lupus nephritis," Arthritis & Rheumatism, vol. 64, no. 1, pp. 232–242, 2012.

[30] J. Faust, J. Menke, J. Kriegsmann et al., "Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Fas/lpr mice with autoimmune lupus nephritis," Arthritis & Rheumatism, vol. 46, no. 11, pp. 3083–3095, 2002.

[31] J. H. Hao, D. Q. Ye, G. Q. Zhang et al., "Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese," Archives of Dermatological Research, vol. 297, no. 7, pp. 329–332, 2006.

[32] N. A. Fathi, M. R. Hussein, H. I. Hassan, E. Mosad, H. Galal, and N. A. Afifi, "Glomerular expression and elevated serum Bcl-2 and Fas proteins in lupus nephritis: preliminary findings," Clinical and Experimental Immunology, vol. 146, no. 2, pp. 339–343, 2006.

[33] C. Miret, J. Font, R. Molina et al., "Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity...
of systemic lupus erythematosus," *Anticancer Research*, vol. 21, no. 4B, pp. 3053–3059, 2001.

[34] E. M. Tan, A. S. Cohen, and J. F. Fries, "The 1982 revised criteria for the classification of systemic lupus erythematosus," *Arthritis & Rheumatism*, vol. 25, no. 11, pp. 1271–1277, 1982.

[35] M. A. Dalboni, C. Sardenberg, M. C. Andreoli et al., "Soluble Fas: a novel marker of inflammation in uremia," *Artificial Organs*, vol. 27, no. 8, pp. 687–691, 2003.

[36] G. C. Tsokos, "Systemic lupus erythematosus," *The New England Journal of Medicine*, vol. 365, no. 22, pp. 2110–2121, 2011.

[37] D. Liang, W. Ma, C. Yao, H. Liu, and X. Chen, "Imbalance of interleukin 18 and interleukin 18 binding protein in patients with lupus nephritis," *Cellular & Molecular Immunology*, vol. 3, no. 4, pp. 303–306, 2006.

[38] N. Calvani, H. B. Richards, M. Tucci, G. Pannarale, and F. Silvestris, "Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis," *Clinical and Experimental Immunology*, vol. 138, no. 1, pp. 171–178, 2004.

[39] T. Tsukinoki, H. Sugiyama, R. Sunami et al., "Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-κB-mediated expression in cultured human mesangial cells," *Clinical and Experimental Nephrology*, vol. 8, no. 3, pp. 196–205, 2004.